Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey

被引:34
作者
Barnett, Brian S. [1 ]
Beaussant, Yvan [2 ]
King, Franklin [3 ,4 ]
Doblin, Rick [5 ]
机构
[1] Cleveland Clin, Dept Psychiat & Psychol, Ctr Behav Hlth, Neurol Inst, Cleveland, OH 44106 USA
[2] Dana Farber Canc Inst, Dept Psychosocia & Oncol & Palliat Care, Boston, MA 02115 USA
[3] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA
[4] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA
[5] Multidisciplinary Assoc Psychedel Studies, Santa Cruz, CA USA
关键词
Psychedelics; survey; psychiatrists; Hallucinogens; psychedelic-assisted therapy; PHYSICIANS ATTITUDES; GUIDELINES;
D O I
10.1080/02791072.2021.1957183
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Despite resurgent interest in psychedelic-assisted therapy, our insights into psychiatrists' knowledge and opinions about medicinal psychedelic applications are surprisingly narrow. Therefore, we anonymously surveyed psychiatrists attending psychedelic didactic presentations at two national meetings about these issues using a 26-item questionnaire. Response rate was 40.20% (106/264). Respondents were 41.73 +/- 13.31 years old (range: 24-80) and 64.42% were male. They largely believed psychedelics show treatment promise and strongly supported federal funding for medicinal psychedelic research. The most common concerns were the lack of trained psychedelic-assisted therapy providers, the logistics of psychedelic-assisted therapy delivery, the administration of psychedelics for patients with contraindications, and diversion. The most desired psychedelic-related educational topics were potential benefits of psychedelic-assisted therapy, how to conduct psychedelic-assisted therapy, psychedelic pharmacology, and psychedelic side effects. Factors associated with increased belief in psychedelics' treatment potential included working primarily in research, scoring higher on a psychedelic knowledge test, and reporting less concern about psychedelics' addictive potential. Working primarily in research and consult-liaison psychiatry fellowship training were positively associated with support for medicinal psychedelic legalization, while increased concerns about addictive potential and attending psychiatrist status were negatively associated. Support for legalization of non-medicinal psychedelic use was negatively associated with age and positively associated with support for legalization of medicinal psychedelic use.
引用
收藏
页码:269 / 277
页数:9
相关论文
共 33 条
  • [1] Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer
    Agin-Liebes, Gabrielle, I
    Malone, Tara
    Yalch, Matthew M.
    Mennenga, Sarah E.
    Ponte, K. Linnae
    Guss, Jeffrey
    Bossis, Anthony P.
    Grigsby, Jim
    Fischer, Stacy
    Ross, Stephen
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2020, 34 (02) : 155 - 166
  • [2] Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study
    Anderson, Brian T.
    Danforth, Alicia
    Daroff, Robert
    Stauffer, Christopher
    Ekman, Eve
    Agin-Liebes, Gabrielle
    Trope, Alexander
    Boden, Matthew Tyler
    Dilley, James
    Mitchell, Jennifer
    Woolley, Joshua
    [J]. ECLINICALMEDICINE, 2020, 27
  • [3] A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens
    Barnett, Brian S.
    Siu, Willie O.
    Pope, Harrison G.
    [J]. JOURNAL OF NERVOUS AND MENTAL DISEASE, 2018, 206 (06) : 476 - 480
  • [4] Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives
    Beaussant, Yvan
    Sanders, Justin
    Sager, Zachary
    Tulsky, James A.
    Braun, Ilana M.
    Blinderman, Craig D.
    Bossis, Anthony P.
    Byock, Ira
    [J]. JOURNAL OF PALLIATIVE MEDICINE, 2020, 23 (10) : 1323 - 1334
  • [5] Hallucinogens and Their Therapeutic Use: A Literature Review
    Begola, Matthew J.
    Schillerstrom, Jason E.
    [J]. JOURNAL OF PSYCHIATRIC PRACTICE, 2019, 25 (05) : 334 - 346
  • [6] Business Wire, 2019, FDA GRANTS BREAKTHRO
  • [7] Calder A, 2020, PSYCHEDELIC SCI REV
  • [8] Trial of Psilocybin versus Escitalopram for Depression
    Carhart-Harris, Robin
    Giribaldi, Bruna
    Watts, Rosalind
    Baker-Jones, Michelle
    Murphy-Beiner, Ashleigh
    Murphy, Roberta
    Martell, Jonny
    Blemings, Allan
    Erritzoe, David
    Nutt, David J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (15) : 1402 - 1411
  • [9] Physician attitudes regarding the prescription of medical marijuana
    Charuvastra, A
    Friedmann, PD
    Stein, MD
    [J]. JOURNAL OF ADDICTIVE DISEASES, 2005, 24 (03) : 87 - 93
  • [10] Compass Pathways, 2018, Compass Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-resistant depression